Research & Development

Developing the leading the treatment for all forms of acute infectious conjunctivitis

We are a clinical stage ophthalmic pharmaceutical company.

We are exclusively focused on developing the leading treatment for acute infectious conjunctivitis (also known as pink eye).

Our lead product candidate, OKG-0303, is being developed to treat acute infectious conjunctivitis. It is a fixed dose eyedrop consisting of a proprietary antiviral, an ocular decongestant and an antibacterial.

Dig Deeper into our Research & Development

Acute Infectious Conjunctivitis

RUBY Trial